Incyte Corporation (Nasdaq: INCY) today announced that new data from its lead cancer programs focused on onco-inflammation, immuno-oncology and myeloproliferative neoplasms will be presented at the 50 th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from May 30 to June 3, 2014, in Chicago.
Data to be presented on June 2 include full results from RECAP, the Phase II trial of ruxolitinib in combination with capecitabine in metastatic pancreatic cancer. This proof-of-concept trial was designed to evaluate the benefits of targeting local and systemic inflammation that adversely impact patient outcomes in pancreatic cancer and many other cancers. Topline results from RECAP, announced in August 2013, showed an overall survival benefit in a pre-specified subgroup analysis of patients. This subgroup consisted of patients with increased levels of serum C-reactive protein (CRP), a well-characterized and readily measurable marker of systemic inflammation.
Also being presented on June 2 are preliminary findings from a Phase I/II study of Incyte’s IDO1 inhibitor, INCB24360, in combination with ipilimumab in patients with metastatic melanoma. This trial was designed to examine potential synergy with other cancer immunotherapies and lay the groundwork for future potential combinations with INCB24360.
On June 3, full results will be presented from the pivotal Phase III RESPONSE trial of ruxolitinib in patients with uncontrolled polycythemia vera (PV), building upon Incyte’s efforts to improve the lives of patients with myeloproliferative neoplasms. RESPONSE is the first Phase III study to evaluate a JAK inhibitor as a treatment for patients with PV. In March 2014, Incyte announced that the RESPONSE trial met its primary endpoint.“These three studies showcase several of the innovative therapies that comprise Incyte’s growing oncology pipeline, including first-in-class compounds in the areas of onco-inflammation and immuno-oncology, which we believe have the potential to transform the way cancer is treated,” stated Hervé Hoppenot, President and Chief Executive Officer, Incyte. “We look forward to sharing the results of these studies in a prestigious oncology forum such as ASCO.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV